Presented by
Natalie Jing Ma
Nominated by
Yale University
Felix Biotechnology was founded in 2019 to accelerate the deployment of novel biotherapeutics treating microbial infections, a growing threat in human health and beyond. It combines cutting-edge synthetic biology technologies from Yale and Berkeley into a pipeline that enables it to target, engineer, and deploy biotherapeutics against a wide range of bacterial infections, including those resistant to existing antibiotics. Felix’s therapies overcome the challenges faced by traditional antibiotics by uniquely target the key mechanisms underlying bacterial antibiotic resistance, driving bacterial evolution to states of antibiotic susceptibility or reduced virulence, and ensuring a treatment option is always available.